Safety signals and pharmacovigilance
Safety signals and pharmacovigilance: 4 articles from Peptides Facts. Evidence-led reference on research peptides.
Signal, Cohort, Trial: Tiers of Drug-Safety Evidence
A spontaneous report, an observational cohort and a randomised trial each answer a different question about harm, and each fails in a characteristic way. This is the harm-measurement counterpart to the site's efficacy framework.
Residual Gastric Content Under GLP-1 Exposure
Ultrasound and endoscopy studies measure more retained stomach content in people exposed to GLP-1 receptor agonists. What they have not measured is the clinical outcome the finding is meant to predict.
Rodent C-Cell Tumours and the Species Question
Lifetime rodent studies found thyroid C-cell tumours with GLP-1 receptor agonists. Whether that finding transfers to people turns on receptor density, calcitonin data and cohort epidemiology, and two regulators read the same package differently.
Semaglutide and NAION: What the Cohort Data Show
A disputed observational signal for optic neuropathy became a labelled very rare adverse effect. The relative risks vary several-fold between studies; the absolute excess is small and better behaved.